Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.

This study has been completed.
Sponsor:
Collaborator:
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Fate Therapeutics
ClinicalTrials.gov Identifier:
NCT00890500
First received: April 28, 2009
Last updated: October 7, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2013
  Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
No publications provided by Fate Therapeutics

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):